Alchemia banks on 2010

By Dylan Bushell-Embling
Thursday, 02 October, 2008

Alchemia [ASX: ACL] has recorded an $11 million loss for the financial year but reports a healthy cash reserve of $15.3 million.

Equity increased from around $87 million to $102 million.

The company expects to go into profit in 2010. Its generic fondaparinux, a copy of GSK’s Arixta, for venous thromboembolism, is scheduled for market launch in the US next year through its partner Dr Reddy’s.

Scientists uncover how cancer cells hide from immune system

By targeting the RNA helicase known as DDX6, scientists could enable the immune system to...

Vanillin flavouring in vapes may disrupt embryo development

Vanillin — a common flavouring chemical in e-cigarettes — may disrupt the normal...

Heart valve tissues created from stem cells

The breakthrough should help advance our understanding into how human heart valves develop,...

Content from other channels on our network

APPEX 2027: The Industry Event Powered by APPMA Returns to Melbourne

From bottleneck to backbone: rethinking water in F&B manufacturing

Barry Callebaut appoints new Chief Operating Officer

Arnott's Group celebrates its suppliers at Sydney event

Record growth for food and grocery manufacturing sector, AFGC reports

UTS pilot project to mitigate methane emissions

Government invests $1.5m in regional science partnerships

Desalination marine works conclude at Belmont

Zip Water releases 2025 Sustainability Report

Australia's EV fleet transition will be won or lost at the depot

Doctor convicted after writing 147 scripts for 96 patients while suspended

Sale of Hobart Private Hospital to Calvary raises concerns

Opinion: The growing risk of AI-driven self-diagnosis in breast health

A new national approach to clinical governance

Opinion: The debate over the government's aged care algorithm is missing the point